Results for tag: "Contrast Induced Nephropathy Drug"

Contrast Induced Nephropathy (CIN) is a type of kidney damage caused by the use of contrast agents during medical imaging procedures. It is a common complication of kidney and liver disorders, and can lead to further complications such as acute kidney injury and chronic kidney disease. Treatment of CIN typically involves the use of drugs that reduce the risk of kidney damage, such as diuretics, ACE inhibitors, and angiotensin receptor blockers. These drugs are used to reduce the risk of CIN by decreasing the amount of contrast agent that reaches the kidneys. Additionally, drugs that reduce inflammation and oxidative stress may be used to reduce the risk of CIN. The Contrast Induced Nephropathy Drug market is a rapidly growing segment of the Liver and Kidney Disorders Drugs market. It is driven by the increasing prevalence of kidney and liver disorders, as well as the growing demand for medical imaging procedures. The market is expected to continue to grow in the coming years, as more drugs are developed to reduce the risk of CIN. Some companies in the Contrast Induced Nephropathy Drug market include AstraZeneca, Pfizer, Merck, Novartis, and Sanofi. Show Less Read more